ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a hold rating to a sell rating in a research report report published on Thursday.

Several other research firms have also commented on PRQR. HC Wainwright raised their price objective on shares of ProQR Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Raymond James raised shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.13.

ProQR Therapeutics Stock Performance

NASDAQ PRQR opened at $3.67 on Thursday. The firm has a 50 day simple moving average of $3.04 and a 200-day simple moving average of $2.27. ProQR Therapeutics has a one year low of $1.33 and a one year high of $4.62. The firm has a market cap of $299.77 million, a price-to-earnings ratio of -11.47 and a beta of 0.26.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Privium Fund Management B.V. lifted its stake in ProQR Therapeutics by 0.9% in the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock worth $10,251,000 after acquiring an additional 51,663 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in ProQR Therapeutics by 14.2% in the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 7,300 shares during the last quarter. Finally, OneDigital Investment Advisors LLC raised its holdings in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 15,550 shares in the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).